Summary:
Stem Cell Innovations is a publicly-traded (SCLL.OB) cell biology company. The company is well positioned to become a leader in the development of next generation drug discovery solutions including human cellular disease models and cell-based therapies. SCI's proprietary stem cell platform named PluriCells (TM) is capable of generating a broad range of differentiated human cell types.
Visit Stem Cell Innovations ( SCI ).

Description (Web site quote):
SCI's core technology focuses on developing, growing, and manipulating human cells in the laboratory using proprietary technology. By growing pure cultures of individual cell types, SCI is currently developing a broad array of human primary cell models as powerful research tools that can form the basis of therapeutic breakthroughs. SCI has established several human pluripotent stem cell lines from fetal gonadal tissue using defined conditions. These PluriCellTM lines have been established directly onto tissue culture plastic without the use of feeder layers or conditioned medium. In addition to the PluriCell technology SCI has already established in vitro hepatocyte screening, kits, compositions, and services for compound toxicity testing, ACTIVTox® and PREDICTIVToxTM.
Visit Stem Cell Innovations ( SCI ).